Clinical trials
Recurrence trials in Ireland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 5 |
| Active, not recruiting | 4 |
| Terminated | 3 |
| Unknown status | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 3 |
| Biogen | 3 |
| Celgene | 3 |
| GlaxoSmithKline | 3 |
| Princess Maxima Center for Pediatric Oncology | 3 |
| Amgen | 2 |
| Novartis Pharmaceuticals | 2 |
| Cancer Trials Ireland | 1 |
| Children's Cancer and Leukaemia Group | 1 |
| Daiichi Sankyo | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 31 |
| Leukemia | 5 |
| Multiple Myeloma | 5 |
| Neoplasms | 5 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 |
| Breast Neoplasms | 3 |
| Multiple Sclerosis | 3 |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Uterine Cervical Neoplasms | 3 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.